title: Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer.
abstract: Recent studies have indicated that the C-reactive protein/ albumin (CRP/Alb) ratio is associated with clinical outcomes in patients with hepatocellular carcinoma (HCC). We examined the prognostic value of this ratio in patients with small-cell lung cancer (SCLC). In this retrospective study, a total of 367 eligible SCLC patients were analyzed and the correlation between the pretreatment CRP/Alb ratio and overall survival (OS) was investigated. The optimal cutoff level of CRP/Alb ratio was at 0.441. A low and high CRP/Alb ratio was assigned to 65.1% and 34.9% of patients, respectively. The median OS of patients with a high CRP/Alb ratio was worse than those in the low group (13.70 vs 18.90 months HR, 1.34; p = 0.005). Disease stage (p < 0.001), performance status (PS) (p < 0.001) and pretreatment LDH (p < 0.001) were also significant predictors of OS. Multivariate analyses showed that the CRP/Alb ratio is an independent prognostic factor (p = 0.025). This study demonstrated that the CRP/Alb ratio could independently predict OS in patients with SCLC, and had comparable prognostic value to other known prognostic markers. Therefore, the CRP/Alb ratio could have prognostic value and be a measurable biomarker in patients with SCLC.
authors.affiliation: 1] Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Ting
authors.initials: T
authors.lastname: Zhou
authors.affiliation: 1] Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Jianhua
authors.initials: J
authors.lastname: Zhan
authors.affiliation: 1] Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Shaodong
authors.initials: S
authors.lastname: Hong
authors.affiliation: 1] Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Zhihuang
authors.initials: Z
authors.lastname: Hu
authors.affiliation: 1] Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Wenfeng
authors.initials: W
authors.lastname: Fang
authors.affiliation: 1] Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Tao
authors.initials: T
authors.lastname: Qin
authors.affiliation: 1] Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Yuxiang
authors.initials: Y
authors.lastname: Ma
authors.affiliation: 1] Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Yunpeng
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
authors.forename: Xiaobo
authors.initials: X
authors.lastname: He
authors.affiliation: 1] Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: 1] Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Huang
authors.affiliation: 1] Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Hongyun
authors.initials: H
authors.lastname: Zhao
authors.affiliation: 1] Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002097:C-Reactive Protein / Q000378:metabolism*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D012709:Serum Albumin / Q000378:metabolism*; D055752:Small Cell Lung Carcinoma / Q000097:blood* / Q000401:mortality*; D015996:Survival Rate
chemical_list: D012709:Serum Albumin; D002097:C-Reactive Protein